Lab
Red Mountain Diagnostics, LLC
Red Mountain Diagnostics, LLC was paid $980K by Medicaid between Jun 2019 and Nov 2024, across 20 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 63% of everything it billed.
33Billing provider infoRED MOUNTAIN DIAGNOSTICS, LLC
HOMEWOOD, AL 35209
HOMEWOOD, AL 35209
33aNPI1225523608assigned 06/27/2018
33bProvider typeClinical Medical Laboratory
28Total paid$980K
24GClaims17,158
24DCodes billed20
24AFirst – last monthJun 2019 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#22 of 61
Median peer was paid$46K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 511 | $49K | |
| 2020 | 9,725 | $583K | |
| 2021 | 6,046 | $305K | |
| 2022 | 658 | $44K | |
| 2024incomplete | 218 | $0.00 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 63% | 10,041 | 4,161 | $615K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 27% | 2,132 | 1,899 | $268K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.2% | 520 | 503 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.1% | 2,191 | 1,047 | $20K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.4% | 76 | 73 | $13K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 422 | 411 | $11K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 613 | 525 | $7K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 78 | 75 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 76 | 73 | $3K |
| 87147 | <1% | 418 | 407 | $2K | |
| 87149 | <1% | 107 | 101 | $2K | |
| 87581 | <1% | 76 | 73 | $2K |
8 more codes
| 87561 | <1% | 76 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 33 | $692.65 |
| 87799 | <1% | 14 | $453.42 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27 | $242.94 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27 | $130.94 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 0% | 13 | $0.00 |
| 88307 | 0% | 117 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 101 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAKE, KAREN (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Lake Psychological Services, LLC | Columbia, SC | $122K |
| Aqua Dermatology of Alabama PC | Vestavia Hls, AL | $65K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.